Intradialytic Parenteral Nutrition

Policy # 00228
Original Effective Date: 02/20/2008
Current Effective Date: 03/13/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Total Parenteral Nutrition and Enteral Nutrition in the Home is addressed in medical policy 00088

When Services Are Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider intradialytic parenteral nutrition (IDPN) as an adjunct to hemodialysis when it is offered as an alternative to a regularly scheduled regimen of total parenteral nutrition only in those patients who would be considered candidates for total parenteral nutrition (TPN) (i.e., a severe pathology of the alimentary tract that does not allow absorption of sufficient nutrients to maintain weight and strength commensurate with the patient’s general condition) to be eligible for coverage.**

Note: This policy only addresses intravenous parenteral nutrition as an adjunct to hemodialysis (not peritoneal dialysis).

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers IDPN as an adjunct to hemodialysis in patients who would not otherwise be considered candidates for TPN to be investigational.*
Intradialytic Parenteral Nutrition

Policy #  00228
Original Effective Date:  02/20/2008
Current Effective Date:  03/13/2023

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers IDPN in patients who would be
considered a candidate for TPN, but for whom the IDPN is not offered as an alternative to TPN, but
in addition to regularly scheduled infusions to TPN to be not medically necessary.**

Background/Overview
Protein Calorie Malnutrition
Protein calorie malnutrition occurs in an estimated 25% to 40% of patients undergoing dialysis. The
cause of malnutrition in patients on dialysis is often multifactorial and may include under dialysis,
chronic inflammation, protein loss in the dialysate solution (particularly in peritoneal dialysis),
untreated metabolic acidosis, and decreased oral intake.

Diagnosis
The clinical evaluation of malnutrition is multifactorial but typically includes measurement of serum
albumin. Serum albumin levels correlate with nutritional status but are imperfect measures of
nutrition because they can be affected by other disease states. Protein calorie malnutrition is
associated with increased morbidity and mortality. For example, the risk of death is increased more
than 10-fold in those whose serum albumin levels are less than 2.5 g/dL, and those with a serum
albumin near the normal range (ie, 3.5-3.9 g/dL) have a mortality rate twice as high as those with an
albumin level greater than 4.0 g/dL.

Treatment
For patients receiving chronic dialysis, the National Kidney Foundation currently recommends a
daily protein of 1.2 g/kg or more in patients undergoing hemodialysis and 1.3 g/kg or more in patients
undergoing peritoneal dialysis. When malnutrition is present, a stepwise approach to treatment is
generally used, beginning with dietary counseling and diet modifications, followed by oral nutrition
supplements, and then by enteral nutrition supplements or parenteral nutrition supplements if
needed.

Intradialytic parenteral nutrition, which refers to the infusion of hyperalimentation fluids at the time
of hemodialysis or peritoneal dialysis, has been investigated as a technique to treat protein calorie
malnutrition in an effort to decrease associated morbidity and mortality. Intradialytic parenteral
nutrition solutions are similar to those used for total parenteral nutrition. A typical solution contains
Intradialytic Parenteral Nutrition

Policy # 00228
Original Effective Date: 02/20/2008
Current Effective Date: 03/13/2023

10% amino acids, 40% to 50% glucose, 10% to 20% lipids, or a mixture of carbohydrate or lipids, depending on patient needs. In hemodialysis, the intradialytic parenteral nutrition infusion is administered through the venous port of the dialysis tubing, typically, 30 minutes after dialysis has begun, and continued throughout the dialysis session.

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**
Total parenteral nutrition solutions are compounded by an individual pharmacy from individual ingredients (eg, dextrose, amino acids, trace elements) into a finished medication based on a prescription and are not required to have approval from the U.S. FDA through a new drug application process. Compounding pharmacies have historically been subject to regulation by state pharmacy boards, although the FDA increased its regulatory oversight under the Drug Quality and Security Act of 2013.

Peritoneal dialysis solutions are regulated as drugs as defined by the FDA. One amino acid-based peritoneal dialysate, Nutrineal™ PD4, 1.1% Amino Acid Peritoneal Dialysis Solution (Baxter), is available commercially outside of the U.S., but has not been FDA approved.

**Rationale/Source**

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Intradialytic parenteral nutrition is the infusion of an intravenous hyperalimentation formula, such as amino acids, glucose, and lipids, during dialysis, to treat protein calorie malnutrition in an effort to decrease the morbidity and mortality experienced in patients with renal failure.

For individuals who are undergoing hemodialysis who receive intradialytic parenteral nutrition, the evidence includes multiple randomized controlled trials, observational studies, and systematic reviews of these studies. The relevant outcomes are overall survival, change in disease status, morbid events, health status measures, quality of life, treatment-related mortality and morbidity. Published
systematic reviews, which included randomized controlled trials but could not pool data, have concluded that the current evidence does not demonstrate benefits in patient outcomes with the use of intradialytic parenteral nutrition for those who would not otherwise qualify for total parenteral nutrition. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Supplemental Information**

**Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

**National Kidney Foundation**

In 2001, the National Kidney Foundation clinical guidelines established target daily protein requirements in patients undergoing chronic dialysis. In 2008, the National Kidney Foundation updated its pediatric nutrition guidelines to recommend a trial of intradialytic parenteral nutrition to augment inadequate nutritional intake for malnourished children (body mass index for height and age <5th percentile) receiving maintenance hemodialysis who are unable to meet their nutritional requirements through oral and tube feeding.

**American Society for Parenteral and Enteral Nutrition**

In 2010, the American Society for Parenteral and Enteral Nutrition issued guidelines on nutritional support in adults in acute and chronic renal failure. The American Society for Parenteral and Enteral Nutrition assigned a level C recommendation (supported by at least one level II investigation) that intradialytic parenteral nutrition should not be used as a nutritional supplement in malnourished chronic kidney disease-V hemodialysis patients. The basis for the recommendation was a large randomized controlled trial that found mortality rates did not differ between malnourished patients receiving intradialytic parenteral nutrition and malnourished patients receiving oral supplements without intradialytic parenteral nutrition. An additional concern was that intradialytic parenteral nutrition “is limited by the need to complete the entire nutrient infusion during the hemodialysis” treatment, which may cause adverse events because of the rapid infusion of glucose and lipids. The American Society for Parenteral and Enteral Nutrition further recommended larger randomized
Intradialytic Parenteral Nutrition

Policy # 00228
Original Effective Date: 02/20/2008
Current Effective Date: 03/13/2023

controlled trials "in malnourished patients are needed to ensure that a clinical benefit of IDPN does not exist."

**U.S. Preventive Services Task Force Recommendations**
Not applicable.

**Medicare National Coverage**
The coverage eligibility of intradialytic parenteral nutrition for Medicare beneficiaries was summarized in a 1996 Health Care Financing Administration ruling, which established that intradialytic nutrition would be considered eligible for coverage only if the patient would otherwise be a candidate for total parenteral nutrition. This ruling reads in part:

"Medicare coverage policies which apply to parenteral and enteral nutrition therapy items and services apply identically to intradialytic parenteral nutrition therapy items and services, because intradialytic parenteral nutrition therapy is a subset of parenteral and enteral nutrition therapy.

... Daily parenteral therapy is ‘considered reasonable and necessary for a patient with severe pathology of the alimentary tract which does not allow absorption of sufficient nutrients to maintain weight and strength commensurate with the patient's general condition.’ Intradialytic parenteral nutrition therapy is administered to end stage renal disease (ESRD) patients while they are receiving dialysis. ESRD patients sometimes undergo parenteral therapy to replace fluids and nutrients lost during dialysis. ESRD patients must meet all of the parenteral nutrition therapy coverage requirements to receive intradialytic parenteral nutrition therapy. Those patients who do not meet all of the parenteral nutrition therapy coverage requirements are ineligible to receive Medicare coverage of intradialytic parenteral nutrition therapy under the prosthetic device benefit...."

The Health Care Financing Administration ruling went on to clarify the benefits for patients who would be considered candidates for total parenteral nutrition and when the intradialytic parenteral nutrition is to be offered in lieu of a regularly scheduled infusion of total parenteral nutrition.

"However, parenteral and enteral nutrition, including intradialytic parenteral nutrition therapy, services and items which are otherwise covered under section 1861(s)(8) can be denied under section 1862(a)(1) for lack of medical necessity.... Example: If a Medicare beneficiary with ESRD, a dialysis patient who meets all of the requirements for coverage of parenteral nutrition therapy,
Intradialytic Parenteral Nutrition

Policy # 00228
Original Effective Date: 02/20/2008
Current Effective Date: 03/13/2023

receives intradialytic parenteral nutrition therapy during dialysis and also receives parenteral
nutrition therapy on the other days of the week when the patient is not on dialysis, it may be
determined that the patient is receiving an excessive number of lipids. A claim for Medicare payment
that is denied because the patient, who qualifies for parenteral nutrition therapy coverage, is
receiving an excessive number of lipids would be denied as not reasonable and necessary under
section 1862(a)(1)(A) of the Act…

Therefore, the precise statutory basis for the coverage or denial of parenteral and enteral nutrition
therapy, including intradialytic parenteral nutrition therapy, services and items is crucial and
determinative as to whether or not limitation on liability protections can be applied."

Ongoing and Unpublished Clinical Trials
One currently unpublished trial that might influence this review is listed in Table 1.

Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04094038</td>
<td>The Effect of Intradialytic Parenteral Nutrition on Nutritional Status and Quality of Life in Hemodialysis Patients</td>
<td>166</td>
<td>Sep 2023</td>
</tr>
</tbody>
</table>

References
PMID 11576926

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 6 of 11
Intradialytic Parenteral Nutrition

Policy # 00228
Original Effective Date: 02/20/2008
Current Effective Date: 03/13/2023


Policy History
Original Effective Date: 02/20/2008
Current Effective Date: 03/13/2023
02/13/2008 Medical Director review
02/20/2008 Medical Policy Committee approval.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 7 of 11
Intradialytic Parenteral Nutrition

Policy #  00228
Original Effective Date:  02/20/2008
Current Effective Date:  03/13/2023

02/04/2009    Medical Director review
02/19/2009    Medical Policy Committee approval. No change to coverage eligibility.
02/04/2010    Medical Policy Committee approval
02/17/2010    Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/03/2011    Medical Policy Committee review
02/16/2011    Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/02/2012    Medical Policy Committee review
02/15/2012    Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/07/2013    Medical Policy Committee review
02/20/2013    Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/06/2014    Medical Policy Committee review
02/19/2014    Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/05/2015    Medical Policy Committee review
02/18/2015    Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/04/2016    Medical Policy Committee review
02/17/2016    Medical Policy Implementation Committee approval. Policy statements edited to clarify that they are intended to apply to parenteral nutrition administered during hemodialysis.
01/01/2017    Coding update: Removing ICD-9 Diagnosis Codes
02/02/2017    Medical Policy Committee review
02/15/2017    Medical Policy Implementation Committee approval. No change to coverage.
02/01/2018    Medical Policy Committee review
02/21/2018    Medical Policy Implementation Committee approval. No change to coverage.
02/07/2019    Medical Policy Committee review
02/20/2019    Medical Policy Implementation Committee approval. No change to coverage.
02/06/2020    Medical Policy Committee review
02/12/2020    Medical Policy Implementation Committee approval. No change to coverage.
02/04/2021    Medical Policy Committee review

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 8 of 11
Intradialytic Parenteral Nutrition

Policy #  00228
Original Effective Date:  02/20/2008
Current Effective Date:   03/13/2023

02/10/2021    Medical Policy Implementation Committee approval. No change to coverage.
02/03/2022    Medical Policy Committee review
02/09/2022    Medical Policy Implementation Committee approval. No change to coverage.
02/02/2023    Medical Policy Committee review
02/08/2023    Medical Policy Implementation Committee approval. No change to coverage.
Next Scheduled Review Date:  02/2024

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.
Intradialytic Parenteral Nutrition

Policy # 00228
Original Effective Date: 02/20/2008
Current Effective Date: 03/13/2023

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>No codes</td>
</tr>
<tr>
<td>HCPCS</td>
<td>B4164, B4168, B4172, B4176, B4178, B4180, B4185, B4189, B4193, B4197, B4199, B4216, B4218, B4220, B4222, B4224, B5000, B5100, B5200</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>N18.1-N18.9, N19</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;

B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
Intradialytic Parenteral Nutrition

Policy # 00228
Original Effective Date: 02/20/2008
Current Effective Date: 03/13/2023

C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

† Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.